Paul Titley at Aesica Pharmaceuticals and Peter York at Crystec Pharma, discuss the design, development and manufacture of modern medicines pose numerous scientific ...

The legislation governing Supplementary Protection Certificates for medicinal products, EU Regulation No. 469/2009 ‘the Regulation’, scores well on brevity but it fa...

Once an inventor has identified a candidate pharmaceutical molecule, the prime objective should be to secure patent protection for the molecule itself together with ...

Over the past decade, Austria has established itself as a well-respected hub of the life science industry. Region by region, the life science industry has spread acr...

Vicki Salmon at IP Asset LLP, last wrote about the proposals for a new patent landscape in Europe last year. The idea of a single patent covering nearly all countrie...